A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
University Health Network, Toronto
Vall d'Hebron Institute of Oncology
BioEclipse Therapeutics
Fate Therapeutics
Fate Therapeutics
BGI, China
Genocea Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Shenzhen Second People's Hospital